CD117 Expression in Squamous Cell Carcinoma of the Oesophagus.

Autor:	Moreira LF; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil lufmoreira@hcpa.edu.br., Maino MM; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil., Garbin HI; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil., DA Natividade GR; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil., Volkweis BS; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil., Kulczynski JU; Southern Surgical Oncology Group, HCPA University Attached Hospital, Faculty of Medicine, Rio Grande do Sul Federal University, Porto Alegre, Brazil.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2018 Jul; Vol. 38 (7), pp. 3929-3933.
DOI:	10.21873/anticanres.12678
Abstrakt:	Background/aim: Identification of changes in specific genes may help new attempts in finding targeted therapy for oesophageal cancer which still has a very poor prognosis. The aim of this study was to investigate CD117 expression in squamous cell carcinoma of the oesophagus (SCCO). Materials and Methods: A preliminary study was performed for CD177 immunoreactivity using a monoclonal antibody against CD117 on 27 SCCO specimens from patients who underwent surgical resection. Specimens of oesophageal mucosa obtained from 10 healthy individuals were studied as a control group. Results: Most patients had TNM American Joint Committee on Cancer stage IIb or III SCCO and mean overall survival was 21 (range=2-72) months. Cytoplasmic membrane CD117 immunoreactivity was demonstrated in only four (15%) out of 27 tumours and in none of the controls. Conclusion: Although immunohistochemical expression of CD117 was higher than previously demonstrated, the lack of expression does not warranty further use in targeted therapy of SCCO. (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu